We were next interested in testing whether splicing alterations observed in SRSF2mt AML cases could be detected in our patient cohort with reduced FBXO11 expression, given that SRSF2 alterations were underpopulated in FBXO11low patients in the BEAT-AML dataset. This evidence concerns the gene FBXO11 and acute myeloid leukemia.